Zevra announces closing of sale of rare pediatric disease priority review voucher for $150 million

Celebration, fla., april 07, 2025 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) (zevra, or the company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of the sale of its rare pediatric disease priority review voucher (prv) for gross proceeds of $150 million.
ZVRA Ratings Summary
ZVRA Quant Ranking